Use of PD-1/PD-L1 inhibitors in non-small cell lung cancer in elderly patients: a meta-analysis and systematic review of randomized clinical trials.
[BACKGROUND] Non-small cell lung cancer (NSCLC) is prevalent and often diagnosed at advanced stages.
- p-value p < 0.001
- 95% CI 0.69-0.84
- 연구 설계 systematic review
APA
Bedin AP, de Castro Neves Carmo Maffezolli G, et al. (2026). Use of PD-1/PD-L1 inhibitors in non-small cell lung cancer in elderly patients: a meta-analysis and systematic review of randomized clinical trials.. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 28(2), 474-483. https://doi.org/10.1007/s12094-025-04027-4
MLA
Bedin AP, et al.. "Use of PD-1/PD-L1 inhibitors in non-small cell lung cancer in elderly patients: a meta-analysis and systematic review of randomized clinical trials.." Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 28, no. 2, 2026, pp. 474-483.
PMID
40779150
Abstract
[BACKGROUND] Non-small cell lung cancer (NSCLC) is prevalent and often diagnosed at advanced stages. Immune checkpoint inhibitors targeting PD-1/PD-L1 pathways have transformed treatment, yet elderly patients remain underrepresented in clinical trials.
[METHODS] We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) comparing PD-1/PD-L1 inhibitors with placebo and/or chemotherapy in elderly patients with NSCLC. Overall survival (OS), Event-Free Survival (EFS) and OS for large studies were evaluated. Random-effects model with 95% confidence intervals were applied.
[RESULTS] Twelve RCTs with 3078 patients were included. PD-1/PD-L1 inhibitors significantly improved OS (HR 0.76; 95% CI 0.69-0.84; p < 0.001) and EFS (HR 0.67; 95% CI 0.54-0.83; p < 0.001). Large studies showed consistent benefit.
[CONCLUSIONS] PD-1/PD-L1 inhibitors significantly improve clinical outcomes in elderly NSCLC patients compared to standard treatments.
[METHODS] We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) comparing PD-1/PD-L1 inhibitors with placebo and/or chemotherapy in elderly patients with NSCLC. Overall survival (OS), Event-Free Survival (EFS) and OS for large studies were evaluated. Random-effects model with 95% confidence intervals were applied.
[RESULTS] Twelve RCTs with 3078 patients were included. PD-1/PD-L1 inhibitors significantly improved OS (HR 0.76; 95% CI 0.69-0.84; p < 0.001) and EFS (HR 0.67; 95% CI 0.54-0.83; p < 0.001). Large studies showed consistent benefit.
[CONCLUSIONS] PD-1/PD-L1 inhibitors significantly improve clinical outcomes in elderly NSCLC patients compared to standard treatments.
MeSH Terms
Aged; Humans; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Immune Checkpoint Inhibitors; Lung Neoplasms; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic